Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-chloro-N,N-dimethyltryptamine (5-Cl-DMT) is a halogenated derivative of N,N-dimethyltryptamine (DMT) and a member of the tryptamine family of psychedelic compounds. It acts as an agonist at several serotonin receptors, most notably 5-HT1A, 5-HT2A, and 5-HT2C, and also inhibits the serotonin transporter (SERT). In preclinical studies, 5-Cl-DMT has been shown to induce the head-twitch response (HTR) in mice, which is a behavioral marker for hallucinogenic activity, although it exhibits lower potency and efficacy in this regard compared to 5-fluoro-DMT. The compound is being investigated for its psychoplastogenic properties, as it upregulates immediate early genes (IEGs) such as Arc and Egr-2 in the prefrontal cortex and hippocampus, indicating a potential for treating mood disorders by promoting structural neuroplasticity. It is currently utilized primarily as a research chemical and analytical reference standard.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-chloro-N,N-dimethyltryptamine.